# A case report of voriconazole therapy failure in a homozygous ultrarapid CYP2C19*17/*17 patient comedicated with carbamazepine

## Metadata
**Authors:** Mirte M Malingré, Peggy C R Godschalk, Saskia K Klein
**Journal:** British Journal of Clinical Pharmacology
**Date:** 2011 Nov 29
**DOI:** [10.1111/j.1365-2125.2011.04156.x](https://doi.org/10.1111/j.1365-2125.2011.04156.x)
**PMID:** 22122271
**PMCID:** PMC3394147
**URL:** https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394147/
**PDF:** [https://pmc.ncbi.nlm.nih.gov/articles/PMC3394147/pdf/bcp0074-0205.pdf](https://pmc.ncbi.nlm.nih.gov/articles/PMC3394147/pdf/bcp0074-0205.pdf)

## Competing Interests

There are no competing interests to declare.

## References

1. Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol. 2010;69:222–30. doi: 10.1111/j.1365-2125.2009.03578.x.  [DOI](https://doi.org/10.1111/j.1365-2125.2009.03578.x) | [PMC free article](/articles/PMC2829691/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/20233192/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Br%20J%20Clin%20Pharmacol&title=Pharmacogenetics%20of%20CYP2C19:%20functional%20and%20clinical%20implications%20of%20a%20new%20variant%20CYP2C19*17&author=A%20Li-Wan-Po&author=T%20Girard&author=P%20Farndon&author=C%20Cooley&author=J%20Lithgow&volume=69&publication_year=2010&pages=222-30&pmid=20233192&doi=10.1111/j.1365-2125.2009.03578.x&)

2. Dolton M, McLachlan A. Clinical importance of the CYP2C19*17 variant allele for voriconazole. Br J Clin Pharmacol. 2011;71:137–8. doi: 10.1111/j.1365-2125.2010.03801.x.  [DOI](https://doi.org/10.1111/j.1365-2125.2010.03801.x) | [PMC free article](/articles/PMC3018036/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/21143511/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Br%20J%20Clin%20Pharmacol&title=Clinical%20importance%20of%20the%20CYP2C19*17%20variant%20allele%20for%20voriconazole&author=M%20Dolton&author=A%20McLachlan&volume=71&publication_year=2011&pages=137-8&pmid=21143511&doi=10.1111/j.1365-2125.2010.03801.x&)

3. Hussaini T, Ruping M, Farowski F, Vehreschild J, Cornelly O. Therapeutic drug monitoring of voriconazole and posaconazole. Pharmacotherapy. 2011;31:214–25. doi: 10.1592/phco.31.2.214.  [DOI](https://doi.org/10.1592/phco.31.2.214) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/21275497/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Pharmacotherapy&title=Therapeutic%20drug%20monitoring%20of%20voriconazole%20and%20posaconazole&author=T%20Hussaini&author=M%20Ruping&author=F%20Farowski&author=J%20Vehreschild&author=O%20Cornelly&volume=31&publication_year=2011&pages=214-25&pmid=21275497&doi=10.1592/phco.31.2.214&)

4. Product information Vfend (voriconazole) EMEA Product Information; date of first authorisation: 21 march 2002, date of last renewal: 21 march 2007.

5. Hassan A, Burhenne J, Riedel K-D, Weiss J, Mikus G, Haefeli W, Czock D. Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring. Ther Drug Monit. 2011;33:86–93. doi: 10.1097/FTD.0b013e31820530cd.  [DOI](https://doi.org/10.1097/FTD.0b013e31820530cd) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/21192313/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Ther%20Drug%20Monit&title=Modulators%20of%20very%20low%20voriconazole%20concentrations%20in%20routine%20therapeutic%20drug%20monitoring&author=A%20Hassan&author=J%20Burhenne&author=K-D%20Riedel&author=J%20Weiss&author=G%20Mikus&volume=33&publication_year=2011&pages=86-93&pmid=21192313&doi=10.1097/FTD.0b013e31820530cd&)
